Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Short term Debt (2017)

Aclaris Therapeutics has reported Short term Debt over the past 1 years, most recently at $590000.0 for Q4 2017.

  • Quarterly results put Short term Debt at $590000.0 for Q4 2017, changed N/A from a year ago — trailing twelve months through Dec 2017 was $590000.0 (changed N/A YoY), and the annual figure for FY2017 was $590000.0, changed.
  • Short term Debt for Q4 2017 was $590000.0 at Aclaris Therapeutics.
  • Over the last five years, Short term Debt for ACRS hit a ceiling of $590000.0 in Q4 2017 and a floor of $590000.0 in Q4 2017.